Dr. Peter A. Kaufman, MD | Burlington ...

Dr. Peter A. Kaufman

Claim this profile

University of Vermont Medical Center

Studies Breast Cancer
Studies Cancer
9 reported clinical trials
24 drugs studied

Area of expertise

1

Breast Cancer

Peter A. Kaufman has run 8 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
HER2 negative
ER positive
2

Cancer

Peter A. Kaufman has run 3 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
HER2 negative

Affiliated Hospitals

Image of trial facility.

The University Of Vermont Medical Center Inc.

Image of trial facility.

University Of Vermont Medical Center

Clinical Trials Peter A. Kaufman is currently running

Image of trial facility.

Lasofoxifene and Abemaciclib vs Fulvestrant and Abemaciclib

for Breast Cancer

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.

Recruiting

2 awards

Phase 3

12 criteria

Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.

Recruiting

2 awards

Phase 3

19 criteria

More about Peter A. Kaufman

Clinical Trial Related

2 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Peter A. Kaufman has experience with

  • Abemaciclib
  • Fulvestrant
  • Imlunestrant
  • Exemestane
  • LY3484356
  • Lasofoxifene

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Peter A. Kaufman specialize in?

Is Peter A. Kaufman currently recruiting for clinical trials?

Are there any treatments that Peter A. Kaufman has studied deeply?

What is the best way to schedule an appointment with Peter A. Kaufman?

What is the office address of Peter A. Kaufman?

Is there any support for travel costs?